Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...
ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback